Sex: M
Vaccine: RSV
Symptoms: Vitamin B12 normal, X-ray limb, X-ray limb abnormal, X-ray of pelvis and hip
Clinical narrative: guillain-barre syndrome; elevated ESR (53); This is a spontaneous report received from a Consumer or other non HCP from Regulatory Authority. Regulatory number: 2718310-1 (VAERS ID).  An 87-year-old male patient received rsv vaccine prot.subunit pref 2v (ABRYSVO), on 24Oct2023 as dose 1, single (Lot number: HF5015) intramuscular, in left arm for immunisation. The patient's relevant medical history included: "A Fib" (unspecified if ongoing); "Diastolic HF" (unspecified if ongoing); "History/Allergies: Statin" (unspecified if ongoing); "Intollerance" (unspecified if ongoing). Concomitant medication(s) included: ALLOPURINOL; FUROSEMIDE; METOPROLOL; WARFARIN. Past drug history included: Azithromycin for Upper respiratory infection, notes: Patient seen in express clinic for upper respiratory infection on 18Oct23 and treated with azithromycin. Vaccination history included: Moderna covid-19 vaccine (DOSE 1, SINGLE), for Covid-19 immunization; Influenza virus vaccine (DOSE 1, SINGLE), for Influenza Immunization; Moderna covid-19 vaccine (DOSE 2, SINGLE), for Covid-19 immunization; Moderna covid-19 vaccine (DOSE 3, SINGLE), for Covid-19 immunization; Moderna covid-19 vaccine (DOSE 4, SINGLE), for Covid-19 immunization; Moderna covid-19 vaccine (DOSE 5, SINGLE), for Covid-19 immunization; Influenza virus vaccine (DOSE 2, SINGLE), for Influenza Immunization; Influenza virus vaccine (DOSE 3, SINGLE), for Influenza Immunization; Influenza virus vaccine (DOSE 4, SINGLE), for Influenza Immunization; Influenza virus vaccine (DOSE 5, SINGLE), for Influenza Immunization; Influenza virus vaccine (DOSE 6, SINGLE), for Influenza Immunization. The following information was reported: GUILLAIN-BARRE SYNDROME (hospitalization, disability, medically significant, life threatening) with onset 12Nov2023, outcome "not recovered"; RED BLOOD CELL SEDIMENTATION RATE INCREASED (non-serious) with onset 15Nov2023, outcome "not recovered", described as "elevated ESR (53)". The patient was hospitalized for guillain-barre syndrome (start date: 18Nov2023, hospitalization duration: 9 day(s)). The patient underwent the following laboratory tests and procedures: Angiogram: (unspecified date) Unknown results; Arteriogram carotid: (unspecified date) Unknown results; Blood lactic acid: (18Nov2023) all within normal limits; Blood thyroid stimulating hormone: (18Nov2023) all within normal limits; Computerised tomogram head: (unspecified date) Unknown results; (unspecified date) Unknown results; C-reactive protein: (15Nov2023) within normal limits; (18Nov2023) within normal limits; (18Nov2023) all within normal limits; Full blood count: (15Nov2023) within normal limits; Imaging procedure: (unspecified date) Unknown results; Magnetic resonance imaging: (unspecified date) Unknown results; Magnetic resonance imaging head: (unspecified date) Unknown results; Magnetic resonance imaging neck: (unspecified date) Unknown results; Magnetic resonance imaging spinal: (unspecified date) Unknown results; Magnetic resonance imaging thoracic: (unspecified date) Unknown results; Metabolic function test: (15Nov2023) within normal limits; Red blood cell sedimentation rate: (15Nov2023) elevated ESR (53); (18Nov2023) ESR (37); (19Nov2023) ESR (33); Ultrasound scan: (unspecified date) Unknown results; Vitamin B12: (18Nov2023) all within normal limits; X-ray limb: (unspecified date) Unknown results; (unspecified date) Abnormal; X-ray of pelvis and hip: (unspecified date) Unknown results; (unspecified date) Unknown results. Therapeutic measures were taken as a result of guillain-barre syndrome.  Additional information: RSV vaccine administered on 24Oct2023. Patient seen in clinic for bilateral leg weakness on 15Nov2023 that started three days prior. Patient seen in emergency department on 18Nov2023 for progressive bilateral leg weakness and failure. Patient admitted to hospital that day with a diagnosis of Guillain- barre syndrome and treated with intravenous immunoglobulin 0.4 g/kg/day x 5 days. Progressive nature of leg weakness ceased after day 1 of [VIG therapy, and gradual return of leg function started to return around day 3 or 4 of therapy. Patient discharged to skilled nursing facility to continue PT/OT as he is not back at his baseline strength as of the time of this report.  No follow-up attempts are possible.